a study on siddha trail drug KUTTATHIRKU CHOORANAM (INT) & VEPPAMPATTAI THYLAM (EXT) & PRANAYAAMAM (THERAPY) in patients having psoriasis

AN OPEN CLINICAL TRAIL ON â??THEATHRU KUTTAM (PSORIASIS)â?? WITH THE EVALUATION ON SIDDHA HERBO-MINERAL FORMULATION KUTTATHIRKU CHOORANAM (INT) & VEPPAMPATTAI THYLAM (EXT) & PRANAYAAMAM (THERAPY).

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/05/013644

Enrollment

Registered

2018-05-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- THEATHRU KUTTAM (PSORIASIS)

Interventions

Intervention1: KUTTATHIRKU CHOORANAM(INT) & VEPPAMPATTAI THYLAM (EXT): 8oo mg of KUTTATHIRKKU CHOORANAM for 48 days as internal medicine and Veppampattai thylam (external) for 48 days as external med

Eligibility

Inclusion criteria

Inclusion criteria: Patches with Scaling Auspitz Sign positive Koebnerâ??s Phenomenon positive.

Exclusion criteria

Exclusion criteria: Psoriasis with secondary infection in the lesions Alcoholism & Narcotic addicts History of long term intake of Steroids Cardiac disease Renal failure Pregnancy women and Lactating women Peptic ulcer Psoriatic Orthopedica

Design outcomes

Primary

Measure	Time frame
outcome is mainly assessed by reduction in clinical symptoms like itching and scaling.PASI Score (Psoriasis area severity index)Timepoint: 12 Months	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactDr K Thirugnanam

government siddha medical college chennai

guidesekar@gmail.com9786193863

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026